SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0000947871-23-000625
Filing Date
2023-05-24
Accepted
2023-05-24 16:47:48
Documents
2
Group Members
ORBIMED CAPITAL GP VI LLCORBIMED CAPITAL LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 ss2112026_sc13da.htm SC 13D/A 115627
2 JOINT FILING AGREEMENT ss2112026_ex9901.htm EX-99.1 5825
  Complete submission text file 0000947871-23-000625.txt   123090
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 200 POWDER MILL ROAD WILMINGTON DE 19803
Business Address 200 POWDER MILL ROAD WILMINGTON DE 19803 (302) 547-3768
Prelude Therapeutics Inc (Subject) CIK: 0001678660 (see all company filings)

IRS No.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91717 | Film No.: 23954834
SIC: 2834 Pharmaceutical Preparations